The current study was undertaken to explore the activity of the AKT inhibitor ipatasertib in combination with other targeted agents covering the pathways downstream of RAS in an mct-spheroid model developed from patient-derived cell lines in the NCI Patient-Derived Models Repository (https://pdmr.cancer.gov/ [cited 2025 May 10]) and established cell lines from the NCI60 tumor cell line panel covering breast, colon, pancreas, prostate, ovary, lung, and head and neck cancers and melanoma. This evidence concerns the gene AKT1 and neoplasm.